Studies have shown that BAFF is commonly overexpressed in SLE and is strongly involved in its pathogenesis.[8] Belimumab, an anti-BAFF monoclonal antibody, has been approved for the treatment of active autoantibody-positive SLE.[9] Recently, Belimumab has been proven efficacious in a variety of SLE disease conditions, such as nephritis and other neuropsychiatric manifestations of SLE,[10,11] while the effect of belimumab on demyelination with SLE remains unclear. Here, TNFSF13B is linked to nephritis.